Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib

References

• PellegritiGFrascaFRegalbutoCSquatritoSVigneriRWorldwide increasing incidence of thyroid cancer: update on epidemiology and risk factorsJ Cancer Epidemiol2013201396521223737785
   PubMedGoogle Scholar
• ChenAJemalAWardEMIncreasing incidence of differentiated thyroid cancer in the United States,1988–2005Cancer2009115163801380719598221
   PubMed Web of Science ®Google Scholar
• Cancer Research UK orgThyroid cancer incidence statistics Available from: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/thyroid/incidence/uk-thyroid-cancer-incidence-statistics-geogAccessed November 5, 2013
   Google Scholar
• National Comprehensive Cancer NetworkThyroid Carcinoma (version 2.2013) Available from: http://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdfAccessed November 5, 2013
   Google Scholar
• National Cancer InstituteSurveillance Epidemiology and End Results Program: SEER Stat Facts: Thyroid Cancer2011 Available from: http://seer.cancer.gov/statfacts/html/thyro.html-incidence-mortalityAccessed November 5, 2013
   Google Scholar
• Eustatia-RuttenCFCorssmitEPBiermaszNRPereiraAMRomijnJASmitJWSurvival and death causes in differentiated thyroid carcinomaJ Clin Endocrinol Metab200691131331916263822
   PubMed Web of Science ®Google Scholar
• DuranteCHaddyNBaudinELong-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapyJ Clin Endocrinol Metab20069182892289916684830
   PubMed Web of Science ®Google Scholar
• ShermanSICytotoxic chemotherapy for differentiated thyroid carcinomaClin Oncol (R Coll Radiol)201022646446820452757
   PubMed Web of Science ®Google Scholar
• WellsSAJrRobinsonBGGagelRFVandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind Phase III trialJ Clin Oncol201230213414122025146
   PubMed Web of Science ®Google Scholar
• EliseiRSchlumbergerMJMüllerSPCabozantinib in progressive medullary thyroid cancerJ Clin Oncol201331293639364624002501
   PubMed Web of Science ®Google Scholar
• PawsonTRegulation and targets of receptor tyrosine kinasesEur J Cancer200238Suppl 5S3S1012528767
   PubMed Web of Science ®Google Scholar
• NikiforovaMNNikiforovYEMolecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosisExpert Rev Mol Diagn200881839518088233
   PubMed Web of Science ®Google Scholar
• Ricarte-FilhoJCRyderMChitaleDAMutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1Cancer Res200969114885489319487299
   PubMed Web of Science ®Google Scholar
• KrauseDSVan EttenRATyrosine kinases as targets for cancer therapyN Engl J Med2005353217218716014887
   PubMed Web of Science ®Google Scholar
• AntonelliAFallahiPFerrariSMDedifferentiated thyroid cancer: a therapeutic challengeBiomed Pharmacother200862855956318725177
   PubMed Web of Science ®Google Scholar
• NikiforovYEThyroid carcinoma: molecular pathways and therapeutic targetsMod Pathol200821Suppl 2S37S4318437172
   PubMed Web of Science ®Google Scholar
• KrollTGSarrafPPecciariniLPAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]Science200028954831357136010958784
   PubMed Web of Science ®Google Scholar
• HouPLiuDXingMFunctional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancerCell Cycle20076337737917297294
   PubMed Web of Science ®Google Scholar
• SajiMRingelMDThe PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumorsMol Cell Endocrinol20103211202819897009
   PubMed Web of Science ®Google Scholar
• MulliganLMKwokJBHealeyCSGerm-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2ANature199336364284584608099202
   PubMed Web of Science ®Google Scholar
• LearoydDLMessinaMZedeniusJRobinsonBGMolecular genetics of thyroid tumors and surgical decision-makingWorld J Surg200024892393310865036
   PubMed Web of Science ®Google Scholar
• HolbroTCivenniGHynesNEThe ErbB receptors and their role in cancer progressionExp Cell Res200328419911012648469
   PubMed Web of Science ®Google Scholar
• Rodríguez-AntonaCPallaresJMontero-CondeCOverexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasisEndocr Relat Cancer201017171619776290
   PubMed Web of Science ®Google Scholar
• BottaroDPRubinJSFalettoDLIdentification of the hepatocyte growth factor receptor as the c-met proto-oncogene productScience199125149958028041846706
   PubMed Web of Science ®Google Scholar
• KleinMPicardEVignaudJMVascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinomaJ Endocrinol19991611414910194527
   PubMed Web of Science ®Google Scholar
• BunoneGVigneriPMarianiLExpression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological featuresAm J Pathol199915561967197610595926
   PubMed Web of Science ®Google Scholar
• KerbelRSTumor angiogenesisN Engl J Med2008358192039204918463380
   PubMed Web of Science ®Google Scholar
• EggoMCHopkinsJMFranklynJAJohnsonGDSandersDSSheppardMCExpression of fibroblast growth factors in thyroid cancerJ Clin Endocrinol Metab1995803100610117533768
   PubMed Web of Science ®Google Scholar
• WescheJHaglundKHaugstenEMFibroblast growth factors and their receptors in cancerBiochem J2011437219921321711248
   PubMed Web of Science ®Google Scholar
• HaugstenEMWiedlochaAOlsnesSWescheJRoles of fibroblast growth factor receptors in carcinogenesisMol Cancer Res20108111439145221047773
   PubMed Web of Science ®Google Scholar
• St BernardRZhengLLiuWWinerDAsaSLEzzatSFibroblast growth factor receptors as molecular targets in thyroid carcinomaEndocrinology200514631145115315564323
   PubMed Web of Science ®Google Scholar
• BergersGHanahanDModes of resistance to anti-angiogenic therapyNat Rev Cancer20088859260318650835
   PubMed Web of Science ®Google Scholar
• DieciMVArnedosMAndreFSoriaJCFibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectivesCancer Discov20133326427923418312
   PubMed Web of Science ®Google Scholar
• PolverinoACoxonAStarnesCAMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenograftsCancer Res200666178715872116951187
   PubMed Web of Science ®Google Scholar
• ShermanSIWirthLJDrozJPMotesanib diphosphate in progressive differentiated thyroid cancerN Engl J Med20083591314218596272
   PubMed Web of Science ®Google Scholar
• SchlumbergerMJEliseiRBastholtLPhase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancerJ Clin Oncol200927233794380119564535
   PubMed Web of Science ®Google Scholar
• CohenEERosenLSVokesEEAxitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a Phase II studyJ Clin Oncol200826294708471318541897
   PubMed Web of Science ®Google Scholar
• LocatiLLicitraLAgateIPhase 2 trial of axitinib for advanced thyroid cancer: preliminary activity resultsPresented at the Fifth European Conference on Head and Neck OncologyPoznan, PolandApril 18–21, 2012
   Google Scholar
• KloosRTRingelMDKnoppMVPhase II trial of sorafenib in metastatic thyroid cancerJ Clin Oncol200927101675168419255327
   PubMed Web of Science ®Google Scholar
• Gupta-AbramsonVTroxelABNelloreAPhase II trial of sorafenib in advanced thyroid cancerJ Clin Oncol200826294714471918541894
   PubMed Web of Science ®Google Scholar
• HoftijzerHHeemstraKAMorreauHBeneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinomaEur J Endocrinol2009161692393119773371
   PubMed Web of Science ®Google Scholar
• AhmedMBarbachanoYRiddellAAnalysis of the efficacy and toxicity of sorafenib in thyroid cancer: a Phase II study in a UK based populationEur J Endocrinol2011165231532221566072
   PubMed Web of Science ®Google Scholar
• BroseMSNuttingCJarzabBSorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: the Phase III DECISION trialJ Clin Oncol201331Suppl Abstr 4
   Google Scholar
• LamETRingelMDKloosRTPhase II clinical trial of sorafenib in metastatic medullary thyroid cancerJ Clin Oncol201028142323233020368568
   PubMed Web of Science ®Google Scholar
• CapdevilaJIglesiasLHalperinISorafenib in metastatic thyroid cancerEndocr Relat Cancer201219220921622285864
   PubMed Web of Science ®Google Scholar
• CohenEENeedlesBMCullenKJPhase 2 study of sunitinib in refractory thyroid cancerJ Clin Oncol200826Suppl Abstr 6025
   Google Scholar
• RavaudAFouchardièreCCourbonFSunitinib in patients with refractory advanced thyroid cancer: the THYSU Phase II trialJ Clin Oncol200826Suppl Abstr 6058
   Google Scholar
• CarrLLMankoffDAGoulartBHPhase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlationClin Cancer Res201016215260526820847059
   PubMed Web of Science ®Google Scholar
• De SouzaJABusaidyNZimrinAPhase II trial of sunitinib in medullary thyroid cancer (MTC)J Clin Oncol201015Suppl Abstr 5504
   Google Scholar
• BibleKCSumanVJMolinaJREfficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a Phase 2 consortium studyLancet Oncol2010111096297220851682
   PubMed Web of Science ®Google Scholar
• BibleKCSumanVJMenefeeMEA multiinstitutional Phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancerJ Clin Endocrinol Metab20129793179318422774206
   PubMed Web of Science ®Google Scholar
• WellsSAJrGosnellJEGagelRFVandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancerJ Clin Oncol201028576777220065189
   PubMed Web of Science ®Google Scholar
• RobinsonBGPaz-AresLKrebsAVasselliJHaddadRVandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancerJ Clin Endocrinol Metab20109562664267120371662
   PubMed Web of Science ®Google Scholar
• LeboulleuxSBastholtLKrauseTVandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, Phase 2 trialLancet Oncol201213989790522898678
   PubMed Web of Science ®Google Scholar
• KurzrockRShermanSIBallDWActivity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancerJ Clin Oncol201129192660266621606412
   PubMed Web of Science ®Google Scholar
• MatsuiJFunahashiYUenakaTWatanabeTTsuruokaAAsadaMMulti-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinaseClin Cancer Res200814175459546518765537
   PubMed Web of Science ®Google Scholar
• GrandeEDiezJJZafonCCapdevilaJThyroid cancer: molecular aspects and new therapeutic strategiesJ Thyroid Res2012201284710822848860
   PubMedGoogle Scholar
• BossDSGlenHBeijnenJHA Phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumoursBr J Cancer2012106101598160422516948
   PubMed Web of Science ®Google Scholar
• ShermanSIJarzabBCabanillasMEA Phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC)J Clin Oncol201129Suppl Abstr 5503
   Google Scholar
• BallDWShermanSIJarzabBLenvatinib treatment of advanced RAI-refractory differentiated thyroid cancer (DTC): cytokine and angiogenic factor (CAF) profiling in combination with tumor genetic analysis to identify markers associated with responseJ Clin Oncol201230Suppl Abstr 5518
   Google Scholar
• SchlumbergerMJarzabBCabanillasMEA Phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC)J Clin Oncol201230Suppl Abstr 5591
   Google Scholar